Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Preventing ibrutinib flare in CLL

Paul Hampel • 10 Jun 2022
EHA 2022
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Venetoclax

In this video, Paul Hampel, MD, Mayo Clinic, Rochester, MN, discusses ibrutinib flare in chronic lymphocytic leukemia (CLL) and methods to prevent this. Dr Hampel first explains how ibrutinib flare occurs, and further emphasizes the importance of better identifying patients at risk for disease flare. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Paul Hampel

1:50
Novel treatment regimens under investigation for Richter's transformation
Paul Hampel • 10 Dec 2023
2:30
Investigating outcomes of patients with SLL: disease-by-compartment
Paul Hampel • 10 Dec 2023
2:38
Ibrutinib treatment for CLL does not increase the incidence of Richter’s transformation
Paul Hampel • 10 Dec 2023
3:31
Clinical considerations when treating patients with CLL with BTK inhibitors
Paul Hampel • 7 Oct 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals